Table 2.

Imaging features of parotid oncocytoma.

No.	First author, year	Age/Sex BHD or not	Pathology	Size (mm)	CT enhancement	MRI T1WI	MRI T2WI	MRI DWI/ADC	MRI T2WI FS	MRI T1WI CE FS	FDG- PET
1	Kasai et al. [10] 2007	56/F	Onc	25	N/A	Hypo	Hypo	High /Low	Iso	Iso	N/A
2	Shah et al. [11] 2007	76/M	Onc	20	Homogeneous	N/A	N/A	N/A	N/A	N/A	Intense FDG uptake
3- 12	Tan et al. [12] 2010	49–74/ 7 female 3 male	Onc	6–66	6 Heterogeneous 4 Homogeneous	N/A	N/A	N/A	N/A	N/A	N/A
13- 21	Patel et al. [13] 2011	N/A 6 female 3 male	8 Onc 1∗	13–34	N/A	9 Hypo	N/A	N/A	8 Iso 1 Hyper∗	8 Iso 1 Hyper∗	N/A
22	Lindor et al. [8] 2012	45/F BHD	Onc	9	N/A	Hypo	Hyper	N/A	N/A	N/A	N/A
23	Sepúlveda et al. [14] 2014	67/F	Onc	73	Heterogeneous	Iso	N/A	N/A	Hyper	Hyper	N/A
24	This report Yoshida et al.	44/F BHD	Clear cell Onc	35	N/A	Hypo	Hypo	High /Low	Hyper	Hypo	N/A

M: male; F: female; Hypo: hypointense; Iso: isointense; Hyper: hyperintense; N/A: not available; T1WI: T1-weighted imaging; T2WI: T2-weighted imaging; DWI: diffusion-weighted images; ADC: apparent diffusion coefficient; T2WI FS: T2-weighted imaging with fat saturation; T1WI CE FS: postcontrast T1-weighted imaging with fat saturation; FDG-PET: ¹⁸F-fluorodeoxyglucose positron emission tomography; Onc: oncocytes. ∗Mixed oncocytoma/pleomorphic adenoma.